for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Takeda Pharmaceutical Co Ltd

4502.T

Latest Trade

3,323.00JPY

Change

-2.00(-0.06%)

Volume

5,664,000

Today's Range

3,287.00

 - 

3,328.00

52 Week Range

2,993.00

 - 

4,365.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
3,325.00
Open
3,316.00
Volume
5,664,000
3M AVG Volume
129.82
Today's High
3,328.00
Today's Low
3,287.00
52 Week High
4,365.00
52 Week Low
2,993.00
Shares Out (MIL)
1,572.83
Market Cap (MIL)
5,260,990.00
Forward P/E
23.76
Dividend (Yield %)
5.41

Next Event

Q3 2022 Takeda Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Takeda Receives Complete Response Letter From The U.S. FDA For TAK-721

Secura Bio Announces U.S. Withdrawal Of Farydak (Panobinostat) NDA

Adage Capital Partners Cuts Share Stake in GE and Honeywell, Ups Share Stake in J&J and Exxon Mobil

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Takeda Pharmaceutical Co Ltd

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

Industry

Major Drugs

Contact Info

4F, 2-1-1, Nihombashihon-cho

CHUO-KU, TKY

103-8668

Japan

+81.3.32782111

https://www.takeda.com/

Executive Leadership

Masahiro Sakane

Chairman of the Board, Independent Director

Christophe Weber

President, Chief Executive Officer, Representative Director

Costa Saroukos

Chief Financial Officer, Director

Andrew S. Plump

President of Research & Development, Vice President of Subsidiary, Director

Masato Iwasaki

Representative Director

Key Stats

2.35 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2019

2.1K

2020

3.3K

2021

3.2K

2022(E)

3.4K
EPS (JPY)

2019

113.500

2020

28.410

2021

240.720

2022(E)

138.417
Price To Earnings (TTM)
11.07
Price To Sales (TTM)
1.55
Price To Book (MRQ)
0.98
Price To Cash Flow (TTM)
5.08
Total Debt To Equity (MRQ)
79.48
LT Debt To Equity (MRQ)
75.44
Return on Investment (TTM)
4.44
Return on Equity (TTM)
3.79

Latest News

Latest News

Takeda submits approval request for Novavax's COVID-19 vaccine in Japan

Takeda Pharmaceutical Co Ltd has submitted an approval request for Novavax's COVID-19 vaccine to Japan's health ministry, the U.S. drugmaker said late on Wednesday.

U.S. FDA approves Takeda's drug for post-transplant CMV infection

The U.S. Food and Drug Administration said on Tuesday it had approved Takeda Pharmaceutical Co Ltd's drug for a common type of viral infection occurring in patients after organ transplant.

Takeda eyeing early 2022 rollout of Novavax's COVID-19 shot in Japan - CEO

Takeda Pharmaceutical Co, the Japanese partner for Novavax Inc's COVID-19 vaccine, is preparing to seek regulatory approval for a roll out in Japan early next year, its top executive said on Friday.

Takeda eyeing early 2022 rollout of Novavax's COVID-19 shot in Japan -CEO

Takeda Pharmaceutical Co, the Japanese partner for Novavax Inc's COVID-19 vaccine, is preparing to seek regulatory approval for a roll out in Japan early next year, its top executive said on Friday.

Japan's Takeda announces share buyback as profit climbs

Japan's Takeda Pharmaceutical Co said on Thursday half-year profit jumped and the drugmaker would buy back shares it viewed as undervalued. Operating profit rose 61% to 346 billion yen ($3.05 billion) in the six months through Sept. 30 from a year ago, driven by strong sales...

Japan's Takeda half-year profit climbs, announces share buyback

Japan's Takeda Pharmaceutical Co said on Thursday that its half-year profit rose 61% as the drugmaker tries to wring synergies out of its acquisition of Shire Plc.

Japan's Takeda says 'human error' caused contamination of Moderna vaccines

Japan's Takeda Pharmaceutical Co Ltd said on Friday that "human error" caused metal contaminants to get into Moderna Inc COVID-19 vaccine doses, leading to a recall.

U.S. FDA approves Takeda's lung cancer therapy

Japanese pharma company Takeda Pharmaceutical Co said on Wednesday the U.S. Food and Drug Administration approved its drug, Exkivity, to treat a type of lung cancer.

Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO

Takeda Pharmaceutical Co, which distributes Moderna Inc's COVID-19 shots in Japan, expects vaccines to become a bigger part of its portfolio as shots for dengue fever and COVID-19 near regulatory approval, its chief executive said.

Japan to purchase 150 million doses of Takeda-produced Novavax vaccines - drugmaker

Takeda Pharmaceutical Co said on Tuesday the Japanese government agreed to purchase 150 million doses of the COVID-19 vaccine it will produce using Novavax Inc's formula.

Moderna to recall COVID-19 doses in Japan after stainless steel contaminants found

Moderna Inc and Takeda Pharmaceutical Co Ltd on Wednesday said they are working with Japanese authorities to recall three batches of COVID-19 vaccine after an investigation found stainless steel contaminants in some vials.

Moderna says Takeda plans to recall three lots of suspended COVID-19 vaccine

Moderna Inc said on Wednesday its Japanese distribution partner, Takeda Pharmaceutical Co Ltd, planned to initiate the recall of three lots of its COVID-19 vaccine that were suspended due to contamination.

Takeda must face Actos antitrust claims, 2nd Circuit says

Takeda Pharmaceutical Co Ltd lost its bid at the 2nd U.S. Circuit Court of Appeals on Wednesday to escape claims that it misdescribed its patents to the U.S. Food and Drug Administration to improperly delay generic versions of its blockbuster diabetes drug Actos.

Takeda settles Intuniv pay-for-delay claims for $1.85 million

Takeda Pharmaceutical Co has agreed to pay $1.85 million to settle claims by consumers that its predecessor Shire PLC delayed the launch of a generic version of its ADHD drug Intuniv through an illegal settlement with generic drugmaker Actavis.

Takeda to record 63 billion yen provision, update Q1 results on Irish tax issue

Takeda Pharmaceutical Co said on Monday it will record a provision of about 63 billion yen ($574.56 million) in its financial statements for the first quarter to reflect a decision by Ireland's tax appeals body relating to tax assessment received by company's unit on a break...

Takeda agrees to supply additional 50 million Moderna COVID-19 vaccines to Japan

Takeda Pharmaceutical Co said on Tuesday it agreed to supply an additional 50 million doses of Moderna Inc's COVID-19 vaccine to Japan.

Takeda says it may double imports of Moderna shots to help accelerate Japan vaccination

Takeda Pharmaceutical Co on Tuesday said it may double imports of Moderna Inc's COVID-19 vaccine to help Japan speed up COVID-19 inoculation efforts that have trailed most wealthy countries.

Takeda reports positive interim results of Moderna trials in Japan

Japanese drugmaker Takeda Pharmaceutical Co, which is importing Moderna Inc 's COVID-19 vaccine into Japan, said interim results of clinical trials ahead of domestic regulatory approvals have been positive.

Novavax expects COVID-19 vaccine supply in Japan well into 2022

Novavax Inc said on Friday the distribution of its COVID-19 vaccine in Japan is expected to begin in late 2021 or early 2022 and continue for the near-term, predicting the need for protection against variants in the future.

Japan to approve Moderna's COVID-19 vaccine as soon as May 21 - Yomiuri

Japanese regulators are set to approve Moderna Inc's COVID-19 vaccine as soon as May 21, the Yomiuri Shimbun newspaper reported Saturday, without citing the source of the information.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up